These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17116867)

  • 1. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.
    Vaccaro C; Bawdon R; Wanjie S; Ober RJ; Ward ES
    Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18709-14. PubMed ID: 17116867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
    Vaccaro C; Zhou J; Ober RJ; Ward ES
    Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.
    Ober RJ; Radu CG; Ghetie V; Ward ES
    Int Immunol; 2001 Dec; 13(12):1551-9. PubMed ID: 11717196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis.
    Zhou J; Mateos F; Ober RJ; Ward ES
    J Mol Biol; 2005 Feb; 345(5):1071-81. PubMed ID: 15644205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
    Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
    Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G.
    Zhou J; Johnson JE; Ghetie V; Ober RJ; Ward ES
    J Mol Biol; 2003 Sep; 332(4):901-13. PubMed ID: 12972260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
    Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
    J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport.
    Stapleton NM; Armstrong-Fisher SS; Andersen JT; van der Schoot CE; Porter C; Page KR; Falconer D; de Haas M; Williamson LM; Clark MR; Vidarsson G; Armour KL
    Mol Immunol; 2018 Mar; 95():1-9. PubMed ID: 29367080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans.
    Firan M; Bawdon R; Radu C; Ober RJ; Eaken D; Antohe F; Ghetie V; Ward ES
    Int Immunol; 2001 Aug; 13(8):993-1002. PubMed ID: 11470769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FcRn for the modulation of antibody dynamics.
    Ward ES; Devanaboyina SC; Ober RJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):131-41. PubMed ID: 25766596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn.
    Kim JK; Firan M; Radu CG; Kim CH; Ghetie V; Ward ES
    Eur J Immunol; 1999 Sep; 29(9):2819-25. PubMed ID: 10508256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.